nach oben

Pituitary

Erschienen in:

01.12.2012

Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient

verfasst von: Daphne D. Dadzie, Esther J. Lee, Catherine A. Monteleone, Stephen H. Schneider

Erschienen in: Pituitary | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Octreotide is widely used as medical therapy for acromegaly. It is known to markedly reduce growth hormone levels, improve symptoms and reduce tumor size. Common side effects include gastrointestinal symptoms, hepatobiliary disorders, dizziness, headaches, bradycardia, hyperglycemia or hypoglycemia and thyroid dysfunction. Although urticaria, allergy/hypersensitivity reactions and anaphylaxis have been noted as possible adverse reactions, there is a lack of data showing a causal relationship between octreotide and hypersensitivity reactions and there is no information on management when continued use of this medication is essential. We now report a case of a 60 year old male with acromegaly who had presented with a cutaneous hypersensitivity reaction to octreotide. In addition he failed treatment with surgery, radiation, and dopamine agonist and could no longer afford to continue treatment with pegvisomant. The patient underwent desensitization treatment for his octreotide allergy and was able to resume treatment without any further side effects. We believe this case represents the first report of successful desensitization treatment for octreotide allergy in an acromegalic patient.

Freda P (2002) Somatostatin analogs in acromegaly. JCEM 87(7):3013–3018PubMed

Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M, Simionescu L, Sandostatin LAR (1996) A promising therapeutic tool in the management of acromegalic patients. Metabolism 45(2):67–71PubMedCrossRef

Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. JCEM 80:3267–3272PubMed

Breier BH, Gallaher BW, Gluckman PD (1991) Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128:347–357PubMedCrossRef

Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. JCEM 86:2779–2786PubMed

Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM (1998) Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 48:311–316CrossRef

Lancranjan I, Atkinson AB (1999) Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group Pituitary 1:105–114

al-Maskari M, Gebbie J, Kendall-Taylor P (1996) The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 45:415–421CrossRef

Cannavo S, Squadrito S, Curto L, Almoto B, Vieni A, Trimarchi F (2000) Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 32:224–229PubMedCrossRef

10.

Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40–47PubMed

11.

Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F (1994) Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131:20–26PubMedCrossRef

12.

Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR (1999) Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 22:409–418PubMed

13.

Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. JCEM 79:145–151PubMed

14.

Giusti M, Gussoni G, Cuttica CM, Giordano G (1996) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian multicenter slow release lanreotide study group. JCEM 81:2089–2097PubMed

15.

Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. JCEM 76:721–727PubMed

16.

Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. JCEM 82:18–22PubMed

17.

Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277–284PubMedCrossRef

18.

Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577–584PubMedCrossRef

19.

Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G (1999) Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. JCEM 84:527–532PubMed

20.

Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pedroncelli A, Tonnarelli GP (1990) Medical management of acromegaly: effects of SMS 201–995 in 30 patients. Endocrinol Exp 24:175–185PubMed

21.

Vance ML, Harris AG (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 151:1573–1578PubMedCrossRef

22.

Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117:711–718PubMed

23.

Sandostatin LAR Drug Center. WebMD. Available from http://www.rxlist.com/sandostatin-lar-drug.htm. Last reviewed on 10/10/11

24.

Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286(1–2):192–198PubMedCrossRef

25.

Octreotide In Facts and Comparison 4.0. Wolters-Kluwer Health. [updated daily; cited 5/27/10] Available from www.FactsandComparisons.com

26.

Gandhi TK, Burstin HR, Cook EF et al (2000) Drug complications in outpatients. J Gen Intern Med 15:149–154PubMedCrossRef

27.

Gandhi TK, Weingart SN, Borus J et al (2003) Adverse drug events in ambulatory care. NEJM 348:1556–1564PubMedCrossRef

28.

DeSchazo RD, Kemp SF (1997) Allergic reactions to drugs and biologic agents. JAMA 278:1895–1906CrossRef

29.

Castells M (2009) Rapid desensitization for hypersentivity reactions to medications. Immunol Allergy Clin N Am 29(3):585–606CrossRef

30.

Solensky R (2006) Drug hypersensitivity. Med Clin North Am 90(1):233–260PubMedCrossRef

31.

Melmed S, Jameson JL (2006) Disorders of the Anterior Pituitary and Hypothalamus. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL (eds) Harrison’s endocrinology. McGraw-Hill, New York, pp 44–48

32.

Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER, Nippoldt TB, Swearingen B, Vance ML, AACE Acromegaly Guidelines Task Force et al (2004) American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10(3):213–225PubMed

33.

Fahlbusch R, Ganslandt O, Buchfelder M, Schott W, Nimsky C (2001) Intraoperative magnetic resonance imaging during transsphenoidal surgery. J Neurosurg 95:381–390PubMedCrossRef

34.

Lombardi G, Colao A, Ferone D et al (1996) Cardiovascular aspects in acromegaly: effects of treatment. Metabolism 45(Suppl 1):57–60PubMedCrossRef

35.

Bevan JS, Atkin SL, Atkinson AB et al (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. JCEM 87:4554–4563PubMed

36.

Abe T, Ludecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137–145PubMedCrossRef

37.

Pichler WJ, Schnyder B, Zanni MP, Hari Y, Von Greyerz S (1998) Role of T cells in drug allergies. Allergy 53:225–232PubMedCrossRef

Titel: Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient
verfasst von: Daphne D. Dadzie
Esther J. Lee
Catherine A. Monteleone
Stephen H. Schneider
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe Sonderheft 1/2012
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-012-0400-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide

Primary hypothyroidism presenting as pseudoacromegaly

Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans’ cell histiocytosis

Be careful …. She has a pituitary gland in her nose

ACTH-producing remnants following apoplexy of an ACTH-secreting pituitary macroadenoma